|
|
||||||||
Laboratoire de Pharmacologie Médicale et Clinique (INSERM U317) (Mrs. Durrieu and Drs. Senard, O. Rascol, Tran, and Montastruc), and the Service de Neurologie (Pr. A Rascol), Centre Hospitalier Universitaire et Faculté de Médecine, Toulouse, France, and Sandoz Laboratories (Dr. Lataste), Basel, Switzerland. G. Durrieu is a fellow of the Association "France-Parkinson."
We found blood pressure (BP), heart rate (HR), plasma norepinephrine (NE), and epinephrine (E) levels in the lying and the standing positions to be similar in never-treated parkinsonian patients (stages 1 and 2) and age-matched controls. CY 208-243, a new centrally active D1 agonist, significantly decreased BP, HR, and NE (but not E) values in the lying position; it elicited orthostatic hypotension and blunted the rise in NE elicited by standing up. These results indicate that the early stages of Parkinson's disease are not accompanied by major changes in autonomie cardiovascular function and suggest the involvement of central D1-receptors in the control of sympathetic tone.
Address correspondence and reprint requests to Prof. Jean-Louis Montastruc, Laboratoire de Pharmacologie Médicale et Clinique, INSERM U317, Faculté de Médecine, 37 allées Jules Guesde, 31073 Toulouse Cedex, France.
Received June 20, 1989. Accepted for publication in final form September 21, 1989.
This article has been cited by other articles:
![]() |
D. S. Goldstein, C. S. Holmes, R. Dendi, S. R. Bruce, and S.-T. Li Orthostatic hypotension from sympathetic denervation in Parkinson's disease Neurology, April 23, 2002; 58(8): 1247 - 1255. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |